Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

October 2017

Feature

Research Reports
Community Oncologists‚ Perception and Adaptability to Emerging Chimeric Antigen T-Cell Therapy
10/16/2017
Chadi Nabhan, MD, MBA, FACP
Yolaine Jeune-Smith, PhD
Peter Klinefelter, BA
Jennifer Fillman, MBA
Bruce A. Feinberg, DO
Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...
Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...
...
10/16/2017
Journal of Clinical Pathways
Perspectives
Potential for Clinical Pathways in Symptom Management
10/16/2017
Gena Cook, BA
Abstract: Clinical pathways are one of the main tools employed across health care to manage quality and consistency. Pathways are also useful for the reduction of variability in cancer care. Clinical pathways in...
Abstract: Clinical pathways are one of the main tools employed across health care to manage quality and consistency. Pathways are also useful for the reduction of variability in cancer care. Clinical pathways in...
...
10/16/2017
Journal of Clinical Pathways

Column

Editor's Page
Integrating Gene Therapy Into Value-Based Care
10/16/2017
Winston Wong, PharmD, Editor-in-Chief
Medical advances emerge swiftly, and sometimes surprisingly. The rapid number of new products approved by the Food and Drug Administration (FDA) for the treatment and care of patients with cancer perfectly...
Medical advances emerge swiftly, and sometimes surprisingly. The rapid number of new products approved by the Food and Drug Administration (FDA) for the treatment and care of patients with cancer perfectly...
...
10/16/2017
Journal of Clinical Pathways
Clinical Pathways GPS
Looking for Leadership in Developing Pathways
10/16/2017
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
Scott Guerin, PhD
A clinical pathway can be defined as an “optimal sequencing and timing of interventions by physicians, nurses, and other staff for a particular diagnosis or procedure.” As organizations new to pathways look to...
A clinical pathway can be defined as an “optimal sequencing and timing of interventions by physicians, nurses, and other staff for a particular diagnosis or procedure.” As organizations new to pathways look to...
A...
10/16/2017
Journal of Clinical Pathways
Pharma Insights
Orphan Drugs: Understanding the Payer Perspective
10/16/2017
Kellie Rademacher, PharmD
Hetty A Lima, BSPharm, RPh, FASHP
New drugs for orphan and rare diseases have the potential to positively impact the lives of patients where historically few or no treatments had been available to manage the disease. The passage of the Orphan Drug...
New drugs for orphan and rare diseases have the potential to positively impact the lives of patients where historically few or no treatments had been available to manage the disease. The passage of the Orphan Drug...
New...
10/16/2017
Journal of Clinical Pathways

News

Conference Coverage
Clinical Pathways Congress
10/16/2017
JCP Editors
The second annual Clinical Pathways Congress (CPC) was held over the weekend of September 8th in Washington, DC. A diverse group of stakeholders representing patients, providers, payers, and the pharmaceutical...
The second annual Clinical Pathways Congress (CPC) was held over the weekend of September 8th in Washington, DC. A diverse group of stakeholders representing patients, providers, payers, and the pharmaceutical...
The...
10/16/2017
Journal of Clinical Pathways

Insights

Interview
Institutional Approaches to Value-Based Care
10/16/2017
  Oncology has emerged as a subspecialty particularly amenable to clinical pathways. As value-based care continues to gain in prominence and importance in practices across the United States, individual providers...
  Oncology has emerged as a subspecialty particularly amenable to clinical pathways. As value-based care continues to gain in prominence and importance in practices across the United States, individual providers...
...
10/16/2017
Journal of Clinical Pathways
Interview
Breakthrough Care Comes at a Cost
10/16/2017
JCP Editors
Gene therapy has captivated the oncology treatment community for years. After promising results in clinical trials, the first generation of gene therapies are being introduced to the market following Food and Drug...
Gene therapy has captivated the oncology treatment community for years. After promising results in clinical trials, the first generation of gene therapies are being introduced to the market following Food and Drug...
Gene...
10/16/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Volume 3

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement